Phase I dose-escalation study of S 78454 in patients with solid tumour Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex versus an oral anti-diabetic in combination with sulfonylurea administered orally for the treatment of type two diabetes Not provided at time of registration and not expected to be available in the future

• Country France
• organs None
• Specialty None

Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Efficacy and safety of the S 05985 combination compared with each individual component: randomised, double-blind, placebo-controlled study over eight weeks in hypertensive patients Not provided at time of registration and not expected to be available in the future

• Country France, Hungary, Latvia, Lithuania, Russian Federation, Ukraine
• organs None
• Specialty None

Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

The EUROPA study: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Clinical efficacy of Valdoxan® in everyday practice conditions (efficiency) Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Clinical acceptability study in patients suffering from chronic venous disease (CVD) comparing micronized purified flavonoid fraction (MPFF) 1000 mg, one tablet daily, to MPFF 500 mg tablet twice a day Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None